Harold N. Lovvorn III

Harold N. Lovvorn III


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2011 in Journal of Surgical Research
Verified
Journal Article
Closed access
JAJason Axt
Jason Axt
AMAndrew Murphy
Andrew Murphy
ESErin H. Seeley
Erin H. Seeley
CMColin A. Martin
Colin A. Martin
CTChase Taylor
Chase Taylor
HIHarold N. Lovvorn III
Harold N. Lovvorn III

1 July 2007 in Neoplasia
Verified
Journal Article
Open access
HIHarold N. Lovvorn III
Harold N. Lovvorn III
JWJenifer Westrup
Jenifer Westrup
SOShaun Opperman
Shaun Opperman
SBScott Boyle
Scott Boyle
GSGenbin Shit
Genbin Shit
MCMark {Ptde} Caestecker
Mark {Ptde} Caestecker
Wilms' tumors, or nephroblastomas, are thought to arise from abnormal postnatal retention and dysregulated differentiation of nephrogenic progenitor cells that originate as a condensed metanephric mesenchyme within embryonic kidneys. We have previously shown that the transcriptional regulator CITED1 (CBP/p300-interacting transactivators with glutamic acid [E]/aspartic acid [D]-rich C-terminal domain) is expressed exclusively in these nephrogenic progenitor cells and is downregulated as they differentiate to form nephronic epithelia. In the current study, we show that CITED1 expression persists in blastemal cell populations of both experimental rat nephroblastomas and human Wilms' tumors, and that primary human Wilms' tumors presenting with disseminated disease show the highest level of CITED1 expression. Unlike the predominantly cytoplasmic subcellular localization of CITED1 in the normal developing kidney, CITED1 is clearly detectable in the nuclear compartment of Wilms' tumor blastema. These findings indicate that CITED1 is a marker of primitive blastema in Wilms' tumors and suggest that persistent expression and/or altered subcellular localization of CITED1 in the condensed metanephric mesenchyme could play a role in Wilms' tumor initiation and pathogenesis.

1 June 2013 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
JAJason Axt
Jason Axt
FAFatmah Abdallah
Fatmah Abdallah
MAMeridith Axt
Meridith Axt
JGJessie Githanga
Jessie Githanga
EHErik Hansen
Erik Hansen
HIHarold N. Lovvorn III
Harold N. Lovvorn III

1 January 2010 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
HIHarold N. Lovvorn III
Harold N. Lovvorn III
DADan Ayers
Dan Ayers
ZZZhiguo Zhao
Zhiguo Zhao
MHMelissa Hilmes
Melissa Hilmes
PPPinki Prasad
Pinki Prasad
JOJames A. O'NEill
James A. O'NEill

1 June 2012 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
AZAmy Zhai
Amy Zhai
JAJason Axt
Jason Axt
EHEmma C. Hamilton
Emma C. Hamilton
EKElizabeth Koehler
Elizabeth Koehler
HIHarold N. Lovvorn III
Harold N. Lovvorn III

26 November 2018 in Children
Verified
Journal Article
Open access
PDF file
HPHannah Phelps
Hannah Phelps
HIHarold N. Lovvorn III
Harold N. Lovvorn III
The application of minimally invasive surgery (MIS) to resect pediatric solid tumors offers the potential for reduced postoperative morbidity with smaller wounds, less pain, fewer surgical site infections, decreased blood loss, shorter hospital stays, and less disruption to treatment regimens. However, significant controversy surrounds the question of whether a high-fidelity oncologic resection of childhood cancers can be achieved through MIS. This review outlines the diverse applications of MIS to treat pediatric malignancies, up to and including definitive resection. This work further summarizes the current evidence supporting the efficacy of MIS to accomplish a definitive, oncologic resection as well as appropriate patient selection criteria for the minimally invasive approach.